Arrowhead Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 4/6
Arrowhead Pharmaceuticals has a total shareholder equity of $173.7M and total debt of $273.7M, which brings its debt-to-equity ratio to 157.6%. Its total assets and total liabilities are $626.3M and $452.6M respectively.
Key information
157.6%
Debt to equity ratio
US$273.69m
Debt
Interest coverage ratio | n/a |
Cash | US$213.38m |
Equity | US$173.71m |
Total liabilities | US$452.57m |
Total assets | US$626.29m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: HDP1's short term assets ($237.9M) exceed its short term liabilities ($63.7M).
Long Term Liabilities: HDP1's short term assets ($237.9M) do not cover its long term liabilities ($388.8M).
Debt to Equity History and Analysis
Debt Level: HDP1's net debt to equity ratio (34.7%) is considered satisfactory.
Reducing Debt: HDP1's debt to equity ratio has increased from 0% to 157.6% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: HDP1 has sufficient cash runway for 6 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: HDP1 is forecast to have sufficient cash runway for 5 months based on free cash flow estimates, but has since raised additional capital.